BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 37395730)

  • 21. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013.
    Beste LA; Leipertz SL; Green PK; Dominitz JA; Ross D; Ioannou GN
    Gastroenterology; 2015 Nov; 149(6):1471-1482.e5; quiz e17-8. PubMed ID: 26255044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features and management issues of NAFLD-related HCC: what we know so far.
    Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A
    Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing liver stiffness is associated with higher incidence of hepatocellular carcinoma in hepatitis C infection and non-alcoholic fatty liver disease-A population-based study.
    Davitkov P; Hoffman K; Falck-Ytter Y; Wilson B; Stojadinovikj G; Anthony DD; Cohen SM; Cooper G
    PLoS One; 2023; 18(1):e0280647. PubMed ID: 36693057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Underrecognition and Suboptimal Quality of Care for Nonalcoholic Fatty Liver Disease Cirrhosis in Primary Care Patients with Diabetes Mellitus.
    Chu JN; Goldman ML; Brandman D; Sohn JH; Islam K; Ross LA; Fox RK
    Am J Med; 2024 Feb; 137(2):172-177.e2. PubMed ID: 37890572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.
    Ueno M; Takeda H; Takai A; Seno H
    World J Gastroenterol; 2022 Jul; 28(27):3410-3421. PubMed ID: 36158261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
    Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
    Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.
    Natarajan Y; Kramer JR; Yu X; Li L; Thrift AP; El-Serag HB; Kanwal F
    Hepatology; 2020 Oct; 72(4):1242-1252. PubMed ID: 32022277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study.
    Reddy KR; McLerran D; Marsh T; Parikh N; Roberts LR; Schwartz M; Nguyen MH; Befeler A; Page-Lester S; Tang R; Srivastava S; Rinaudo JA; Feng Z; Marrero JA
    Gastroenterology; 2023 Oct; 165(4):1053-1063.e6. PubMed ID: 37429366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease.
    Zhang X; Wong GL; Yip TC; Cheung JTK; Tse YK; Hui VW; Lin H; Lai JC; Chan HL; Kong AP; Wong VW
    Hepatology; 2022 Nov; 76(5):1409-1422. PubMed ID: 35334125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced liver fibrosis and the metabolic syndrome in a primary care setting.
    Schreiner AD; Zhang J; Durkalski-Mauldin V; Livingston S; Marsden J; Bian J; Mauldin PD; Moran WP; Rockey DC
    Diabetes Metab Res Rev; 2021 Nov; 37(8):e3452. PubMed ID: 33759300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Cernea S; Onișor D
    World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational HCC screening approaches for patients with NAFLD.
    Singal AG; El-Serag HB
    J Hepatol; 2022 Jan; 76(1):195-201. PubMed ID: 34508791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
    Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY
    Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy.
    Polyzos SA; Chrysavgis L; Vachliotis ID; Chartampilas E; Cholongitas E
    Semin Cancer Biol; 2023 Aug; 93():20-35. PubMed ID: 37149203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the FIB-4 liver fibrosis index.
    Suh B; Yun JM; Park S; Shin DW; Lee TH; Yang HK; Ahn E; Lee H; Park JH; Cho B
    Cancer; 2015 Nov; 121(21):3818-25. PubMed ID: 26178294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study.
    Pinyopornpanish K; Khoudari G; Saleh MA; Angkurawaranon C; Pinyopornpanish K; Mansoor E; Dasarathy S; McCullough A
    BMC Gastroenterol; 2021 Oct; 21(1):394. PubMed ID: 34674650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
    Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
    Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.